Astria Therapeutics to present patient survey data at the 2023 HAEi Regional Conference EMEA
Astria Therapeutics Inc, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy, at the upcoming 2023 HAEi Regional Conference EMEA in Munich, Germany from September 1-3, 2023.
Remy Petersen, MD, Amsterdam University Medical Center, will present: ‘People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as a Target for Therapeutic Efficacy’ in a poster session beginning on Friday, September 1, at 7:30pm CEST.
(Source: Astria Therapeutics)
